Hiddo J.L. Heerspink

Author

University Medical Center Groningen ORCID

Also Known As

Arie M. van Roon, C.J. Daiss, Clint Hurst, David Cherney, H Heerspink, H J L Heerspink, H J Lambers Heerspink, H Lambers Heerspink, H. Heerspink, H. J. L. Heerspink

1.1K

Publications

61.6K

Citations

117

H-Index

Concepts

All Affiliations

University Medical Center Groningen University of Groningen The George Institute for Global Health University of Copenhagen UNSW Sydney

About

Hiddo J.L. Heerspink is an author at University Medical Center Groningen specializing in chronic kidney disease, medicine, and nephrology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	47	85	10.3K
2	Health Sciences	10	10	539
3	Public Health	8	8	506
4	Engineering	1	1	18
5	Biochemistry	1	1	167

Hiddo J.L. Heerspink

363

Publications

39.5K

Citations

H-Index

Page 1

	Year	Citations
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy Vlado Perkovic, Meg Jardine, Bruce Neal, New England Journal of Medicine	2019	5.7K
Dapagliflozin in Patients with Chronic Kidney Disease Hiddo J.L. Heerspink, Bergur V. Stefánsson, Ricardo Correa‐Rotter, New England Journal of Medicine	2020	4.8K
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease Dick de Zeeuw, Tadao Akizawa, Paul Audhya, New England Journal of Medicine	2013	969
Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes Hiddo J.L. Heerspink, Dick de Zeeuw, Li Wie, Diabetes Obesity and Metabolism	2013	801
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial Ofri Mosenzon, Stephen D. Wiviott, Avivit Cahn, The Lancet Diabetes & Endocrinology Metabolic SyndromeDeclare–timi 58Diabetes ManagementRenal DiseaseChronic Kidney Disease	2019	656
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress, The Lancet UrologyRenal DiseaseRenal EventsRenal FunctionDiabetes	2019	589
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency Andrew S. Levey, Ron T. Gansevoort, Josef Coresh, American Journal of Kidney Diseases GlomerulonephritisHemodialysisRenal FunctionRenal DiseaseNational Kidney Foundation	2019	529
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial David C. Wheeler, Bergur V. Stefánsson, Niels Jongs, The Lancet Diabetes & Endocrinology Metabolic SyndromeHypertensionRenal FunctionRenal DiseaseCardiovascular Disease	2020	498
Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease Hiddo J.L. Heerspink, Paul Perco, Skander Mulder, Diabetologia	2019	441
Randomized, Double-Blind, Placebo-Controlled, Multicentre Pilot Study on the Effects of Empagliflozin on Clinical Outcomes in Patients with Acute Decompensated Heart Failure (EMPA-RESPONSE-AHF) Kevin Damman, Joost C. Beusekamp, Eva M. Boorsma, European Journal of Heart Failure	2020	427

Page 1